Resistance management of ibrutinib/ibrutinib

Ibrutinib/Ibrutinib is an oral small molecule drug mainly used to treat a variety of B-cell malignancies, such as chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), etc. However, with its widespread application and longer use time, drug resistance problems have gradually emerged. The emergence of drug resistance not only affects the therapeutic effect of ibrutinib, but also brings greater treatment challenges to patients. Therefore, the treatment of ibrutinib resistance is particularly important.

The mechanisms of ibrutinib resistance are complex and diverse, and may involve multiple aspects such as genetic mutations, changes in drug metabolism, and tumor microenvironment. For these mechanisms, drug resistance treatment strategies also need to consider many aspects. The occurrence of drug resistance may be due to individual genetic variations. Therefore, understanding a patient's genetic information can help doctors develop individualized treatment plans and choose more appropriate drugs or therapies.

Regular monitoring of patients for efficacy and resistance is very important. By detecting disease indicators and related gene mutations in patients' blood, signs of drug resistance can be detected early and treatment plans can be adjusted in a timely manner. Combination therapy strategies can effectively reduce ibrutinib resistance. Combining ibrutinib with other drugs, such as chemotherapy drugs, antibody drugs or other targeted therapy drugs, may produce a synergistic effect and improve the therapeutic effect.

In addition, with the continuous deepening of medical research, new drug resistance treatment strategies are also emerging. For example, gene editing technology is used to directly repair mutations in drug-resistant genes; immunotherapy is used to activate the patient's own immune system to attack tumor cells. These new strategies provide more possibilities for the management of ibrutinib resistance.